Drug Profile
Cadisegliatin - vTv Therapeutics
Alternative Names: GK1-399; GKI399; TTP-399Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer CinRx Pharma; vTv Therapeutics LLC
- Class Antihyperglycaemics; Cyclohexanes; Ethers; Small molecules; Sulfhydryl compounds; Thiazoles
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Type 1 diabetes mellitus
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 20 Mar 2024 vTv Therapeuics plans two international registrational studies for Type I diabetes mellitus in 2026
- 13 Mar 2024 vTv Therapeutics plans a phase III registrational trial for Type 1 diabetes mellitus (Adjunctive treatment) in the second quarter of 2024 (PO)
- 04 Mar 2024 vTv Therapeutics plans a phase II trial for Type 2 diabetes mellitus (Adjunctive treatment) in middle eastern countries in 2024 (PO)